Increased signaling due to upregulation of Wnt ligands, specifically Wnt5a, contributes to poor clinical outcome and increased drug resistance, e.g., in ovarian carcinoma and lung cancer [16,32]. Here, WNT5A is linked to ovarian carcinoma.